Sellas Life Sciences Group Inc
F:RXK3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sellas Life Sciences Group Inc
F:RXK3
|
US |
Intrinsic Value
The intrinsic value of 
Sellas Life Sciences Group Inc (RXK3) under the Base Case is 1.2 EUR per share.
Compared with the current market price of 10.05 EUR, the stock appears
Overvalued by 88% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Sellas Life Sciences Group Does
Sellas Life Sciences Group is a clinical-stage biopharmaceutical company focused on cancer treatment. It develops drug candidates that aim to help the immune system attack tumors and to improve how certain hard-to-treat cancers are managed. Its work centers on oncology, with a pipeline of experimental therapies that are still going through testing and regulatory review.
- Headquarters
- United States of America US
- Employees
- 13
- IPO date
- Mar 12, 2008
Revenue & Expenses Breakdown
Sellas Life Sciences Group Inc
Earnings Waterfall
Sellas Life Sciences Group Inc
The intrinsic value for Sellas Life Sciences Group Inc (RXK3) under the Base Case is 1.2 EUR.
Compared with the current market price of 10.05 EUR, the stock appears Overvalued by 88% .